Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study

Background: Patients with bone metastases from solid tumors often have additional treatment with bone targeted agents (BTAs) to avoid symptomatic skeletal events (SSEs) such as clinically significant pathological fracture leading toradiation therapy or surgery to the bone, spinal cord compression, o...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Bone Reports
المؤلفون الرئيسيون:	Michael Mark, Alfonso Rojas Mora, Thomas Winder, Anastasios Stathis, Andreas Jakob, Gisela Müller, Stefanie Hayoz, Patrick Reimann, Ulf Petrausch, Roger von Moos
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Elsevier 2024-09-01
الموضوعات:	Bone metastases Bone-targeting agents Skeletal-related events Symptomatic skeletal events Immunotherapy
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2352187224000615